Melanotan 2 Dosage: Loading, Maintenance and Reconstitution
Melanotan 2 (MT-II) is a synthetic melanocortin peptide with observed pigmentation effects in a small human study. Online loading and maintenance routines go beyond that evidence. This guide keeps those proposed dose ranges in view while separating them from tested outcomes, concentration arithmetic and documented safety signals. For background chemistry and how MT-I and MT-II differ, start with the tanning peptides overview.
Melanotan 2 Dosage Chart: Quick Reference
These are proposed routines discussed in the community, not prescribing instructions or validated phase lengths. A smaller starting amount does not establish safety, and a change in skin color does not validate the schedule.
| Phase | Dose | Frequency | Duration | Evidence status |
|---|---|---|---|---|
| Proposed starter | 250 mcg | Once daily | Days 1–3 | Not a validated tolerability test |
| Proposed loading | 500 mcg | Once daily | 1–3 weeks | No validated escalation or skin-type timeline |
| Proposed maintenance | 500 mcg–1 mg | 1–2× weekly | No established duration | Long-term efficacy and safety not established |
The Loading Phase
The proposed 250-to-500 mcg ladder should not be confused with the 1996 Dorr and colleagues pilot. Three men received alternating MT-II and saline injections across two weeks, with five active subcutaneous doses each. The study used weight-based escalation from 0.01 mg/kg to 0.03 mg/kg in two participants and 0.025 mg/kg in the third. Two showed increased pigmentation one week after dosing ended. This is evidence of biological activity, not a tested community loading schedule or predictable time to a desired shade.
The small sample cannot establish a separate dosing rule for fair, burn-prone or darker skin, nor does it show that increasing a dose when color develops slowly improves the benefit-risk balance. Individual tanning anecdotes can describe an experience without establishing why it occurred or how reliably another person would respond.
The Maintenance Phase
The proposed 500 mcg to 1 mg once- or twice-weekly routine is not a maintenance schedule established by the cited trial. Skin color and circulating peptide exposure are different measurements: visible pigment can persist without proving that a particular repeat dose is needed. The sources reviewed do not establish a safe ongoing duration, a fading-color dose adjustment or a cycling break that prevents adverse effects.
Reconstitution Math
For a mathematical example, 10 mg is 10,000 mcg. In a final solution volume of 2 mL, that gives 5000 mcg/mL: 250 mcg occupies 0.05 mL and 500 mcg occupies 0.1 mL. On a U-100 scale these volumes correspond to 5 and 10 units. They are volume markings, not biological IU or a count of individual tick marks on every syringe.
A final volume of 1 mL instead gives 10,000 mcg/mL. Now 250 mcg occupies 0.025 mL, or 2.5 U-100 units. That smaller volume can be harder, not easier, to measure on a device without suitable graduations. Neither calculation establishes the amount actually in an online vial, its sterility, a compatible solvent or a beyond-use date. The peptide storage guide and how to reconstitute peptides explain general concepts; they do not replace product-specific preparation and storage instructions.
Injection and UV Exposure
The human pilot used subcutaneous injections. That does not make every product labeled MT-II suitable for injection, and a nasal spray cannot be converted to an injection dose by matching the printed mass. Our how to inject peptides guide addresses general technique, not the suitability or sterility of a particular MT-II product.
It is not established here that MT-II needs a UV trigger to produce pigmentation. Equally, the pilot abstract does not isolate a completely UV-free condition, so it cannot quantify how much color would develop with zero exposure. Neither point supports prescribing sunbeds or deliberate extra sun exposure. UVA and UVB can damage skin; tanning color is not evidence that MT-II prevents sunburn or skin cancer. UV protection remains important regardless of appearance.
Side Effects and Skin Monitoring
The pilot reported nausea and spontaneous erections, with marked sleepiness and fatigue in one of the two participants exposed to its highest dose. That small study does not establish how often these effects occur in community use or that nausea reliably disappears with continued dosing. Reports of flushing or appetite changes likewise should not be turned into a precise incidence estimate without an appropriate denominator.
A published MT-II case describes ischemic priapism requiring surgery. An erection lasting four hours or longer needs emergency care; a painful, persistent erection warrants prompt assessment rather than waiting for it to settle. This is a specific complication to recognize, not a claim that every erection becomes priapism. See the AUA/SMSNA acute ischemic priapism guideline.
New or changing moles and dark spots deserve assessment, not automatic attribution to a cosmetic effect. A 2026 report of multiple melanomas in situ involved self-reported MT-II followed by MT-I, tanning-bed exposure and other risk factors. The authors could not establish causality from that single case. Such reports are signals to investigate; they neither prove MT-II caused the cancers nor establish that its long-term cancer risk is absent. Skin checks can identify changes but do not certify a regimen as safe.
Product content is another uncertainty. In August 2026 Australian laboratory testing, five seized nasal sprays labeled as containing 30 mg had estimated contents of 22–54 mg, calculated using the labeled 20 mL volume. That finding concerns those sprays, not every vial or US pharmacy, but illustrates why label-based arithmetic alone cannot verify an untested product.
Legal and Regulatory Status
MT-II is not an FDA-approved tanning medicine. FDA has documented enforcement against its marketing as an unapproved injectable tanning drug. Its current compounding safety page also identifies MT-II concerns, including peptide impurities and immunogenicity. A withdrawn nomination is not an approval. Approval, compounding eligibility, marketing and personal possession are separate issues; online availability or a research-use label does not establish lawful supply for human treatment.
The related but distinct PT-141 (bremelanotide) has an approved product, Vyleesi. Its US label is for acquired, generalized hypoactive sexual desire disorder in premenopausal women when the distressing low desire is not explained by a medical or psychiatric condition, relationship problems, or a medication or drug. It is not approved for tanning, male erectile dysfunction or general performance enhancement. This product-specific approval does not transfer to MT-II or an online PT-141 vial.
Frequently Asked Questions About Melanotan 2
The 250 mcg daily starter followed by 500 mcg daily is a proposed community routine, not a validated standard. The small human pigmentation pilot used a different weight-based schedule. It does not establish a one-to-three-week loading phase, a skin-type dosing rule or a safe escalation plan.
The proposed 500 mcg to 1 mg once or twice weekly routine is not an established maintenance dose. Persistence of skin color does not prove that this schedule is effective or safe long term. The reviewed evidence does not establish a dose-adjustment rule based on fading color.
For arithmetic only, 10 mg in a final solution volume of 2 mL equals 5000 mcg/mL: 250 mcg occupies 0.05 mL and 500 mcg occupies 0.1 mL. Those are 5 and 10 units on a U-100 scale. At a final volume of 1 mL, 250 mcg occupies only 0.025 mL, or 2.5 U-100 units, which may be harder to measure. These calculations do not specify a compatible diluent, sterility or storage life.
The blanket claim that MT-II cannot produce pigmentation without a UV trigger is not established by the evidence reviewed here. The pilot demonstrated pigmentation, but its abstract does not isolate the effect of completely avoiding UV. That uncertainty is not a reason to prescribe sunbeds or extra sun exposure; UV can damage skin, and a darker appearance is not proof of protection.
The cited human pilot used subcutaneous administration. That research route does not establish that an online vial is injectable, sterile or equivalent to the study preparation. A general technique guide cannot supply missing product-specific preparation, route or device instructions, and nasal and injected amounts are not interchangeable.
The small pilot reported nausea, erections and dose-related sleepiness or fatigue. Skin changes and serious events also appear in case reports, which cannot provide reliable frequency estimates or prove every event was caused by MT-II. Seek emergency care for an erection lasting four hours or longer; get a new or changing skin lesion assessed rather than assuming it is a harmless tanning effect.
MT-II is not an FDA-approved tanning medicine. FDA has taken enforcement action against its marketing as an unapproved injectable tanning drug. Approval, lawful compounding, marketing and personal possession are different questions; neither online availability nor a research-use label establishes that a product can lawfully be supplied for human treatment.
PT-141 is bremelanotide, a related but distinct melanocortin peptide. Its approved product Vyleesi treats acquired, generalized hypoactive sexual desire disorder in eligible premenopausal women, not tanning, male erectile dysfunction or general sexual performance. That approval does not transfer to MT-II or to an online PT-141 research vial.